藥明生物(02269.HK):2023年新增132個項目,項目總數達到698個
格隆匯1月10日丨藥明生物(02269.HK)公佈,公司將於20241年1月11日(香港時間)出席第42屆年度摩根大通醫療健康大會("年度醫療健康大會"),會上將進行包含公司業務營運的若干資訊的簡報("簡報")。為確保公司所有股東及潛在投資者能夠公平及時地取得該等信息,公司於公吿納入簡報全文。公司股東及潛在投資者務請注意,簡報可能包含前瞻性陳述,該等陳述就其性質而言存在風險及不確定性,簡報中陳述的任何估計及未來建議均基於若干假設及估計以及管理層僅根據當前可得資料作出的判斷。
誠如簡報中所披露,公司的業務及財務狀況依然強勁,於2023年新增132個項目,項目總數達到698個(其中包括9個III期及商業化"贏得分子"項目,以及24個CMO項目)。該等項目驗證了客户對公司的CMO能力及規模的信任及認可,CMO項目數的增加將進一步提升公司近期收益。透過"跟隨分子"策略以及提升建立多個技術平台以賦能多種技術的能力,公司有信心在2024年繼續實現穩健增長,並對未來充滿信心。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.